Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Novocure
< Previous
1
2
3
Next >
Novocure Reports Second Quarter 2024 Financial Results
July 25, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure to Report Second Quarter 2024 Financial Results
July 01, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
June 03, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
May 02, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Reports First Quarter 2024 Financial Results
May 02, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
April 24, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure to Report First Quarter 2024 Financial Results
April 01, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
March 27, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
March 11, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
February 22, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
January 18, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
January 09, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
January 08, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
January 04, 2024
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
November 28, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
November 21, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
November 10, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Reports Third Quarter 2023 Financial Results
October 26, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
October 15, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
October 12, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure to Report Third Quarter 2023 Financial Results
October 02, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
September 29, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
September 08, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
August 29, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
August 28, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure to Participate in Upcoming Investor Conferences
August 25, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Reports Second Quarter 2023 Financial Results
July 27, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
July 21, 2023
From
Novocure
Via
Business Wire
Tickers
NVCR
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit